

**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW



RECEIVED

JAN 12 2004
TECH CENTER 1600/2900

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbalis
Michael B. Ray
Robert E. Sokol
Eric K. Stoff
Michael Q. Lee
Steven R. Ludwig
John M. Cowert
Linda E. Alcom
Robert C. Millonig
Lawrence B. Bugalsky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Heldi L. Kraus
Edward W. Yee
Albert L. Ferro
Donald R. Banowitz
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaton
Kimberly N. Reddick

Theodore A. Wood
Elizabeth J. Haznes
Bruce E. Chaffler
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Uhler
Rae Lynn Prengaman
Jane Shershenovich
Lawrence J. Carroll
George S. Bardmesser
Daniel A. Klein
Jason D. Elsenberg
Michael D. Spectri
Andrea J. Kamage
Tracy L. Muller
Jon E. Wright
LuAnne M. Turicek
John J. Figueroa

Ann E. Summerfield
Tiera S. Coston*
Aric W. Ledford*
Registered Patent Agents
Karen R. Markowitz
Nancy J. Leigh
Helene C. Carlson
Gabby L. Longworth
Matthew J. Dowd
Aaron L. Schwartz
Mary B. Tung
Kathia Y. Pei Quach
Bryan A. Skelton
Robert A. Schwartzman
Timothy A. Doyle
Jennifer R. Mahalingappa

1647/15
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford
Eric D. Hayes

Of Counsel
Kenneth C. Bass II
Evan R. Smith

*Admitted only in Maryland
*Admitted only in Virginia
*Practice limited to
Federal Agencies

December 30, 2003

WRITER'S DIRECT NUMBER:
(202) 772-8525
INTERNET ADDRESS:
BRIAND@SKGF.COM

Art Unit 1647

Re: U.S. Utility Continuation Patent Application
Appl. No. 09/877,244; Filed: June 11, 2001
For: Use of Vascular Endothelial Growth Factor (VEGF)
Inventors: STADDON *et al.*
Our Ref: 0623.1090001/LBB/BJD

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Credit Card Payment Form (PTO-2038) in the amount of \$950.00 to cover the appropriate fees;
2. PTO Fee Transmittal (PTO/SB/17);
3. Petition For Extension of Time Under 37 C.F.R. § 1.136(a);
4. Amendment and Reply Under 37 C.F.R. § 1.111; and
5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
December 30, 2003
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

LBB/BJD/nef
Enclosures

::ODMA\HODMA\SKGF_DC1:212681;1
SKGF Rev. 2/15/02 dcw; 4/18/03 svb



RECEIVED
JAN 12 2004
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

STADDON *et al.*

Appl. No. 09/877,244

Filed: June 11, 2001

For: **Use of Vascular Endothelial
Growth Factor (VEGF)**

Confirmation No. 9543

Art Unit: 1647

Examiner: Landsman, R.S.

Atty. Docket: 0623.1090001/LBB/BJD

Amendment and Reply Under 37 C.F.R. § 1.111

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the non-final Office Action dated June 30, 2003 (PTO Prosecution File Wrapper Paper No. 10), Applicants submit the following amendments and remarks. In accordance with 37 C.F.R. § 1.121, this Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, a listing of amendments to the specification;
- (C) Starting on a separate sheet, a complete listing of all the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims; and
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this

application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.